2017年9月1日 · Discovery of vimseltinib (DCC -3014), a highly selective switch -control inhibitor of CSF1R kinase. Phase 1 Dose-Escalation Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DCC-3014 in Advanced Solid Tumors and Tenosynovial Giant Cell Tumor (TGCT) (NCT3069469).

2022年10月15日 · Structure Activity Relationship optimization in a novel series of dihydropyrimidone-based CSF1R kinase inhibitors led to the discovery of compound 20 (DCC-3014, vimseltinib), a potent and highly selective inhibitor of CSF1R kinase, displaying favorable drug-like profile.

2022年10月15日 · Starting with lead compound 3, an SAR optimization campaign led to the discovery of vimseltinib (DCC-3014; compound 20) currently undergoing clinical evaluation for the treatment of Tenosynovial Giant Cell Tumor (TGCT), a locally aggressive benign tumor associated with substantial morbidity. 2021 Elsevier ltd.

vimseltinib (DCC-3014), a highly selective switch-control inhibitor of CSF1R kinase Timothy M. Caldwell, Yu Mi Ahn, Gary E. Brandt, Lara E. Davis, Michael Kaufman, Keisuke Kuida, Cynthia B. Leary, Wei Ping Lu, William C. Patt, Thiwanka B. Samarakoon, Rodrigo Ruiz-Soto, Maitreyi Sharma, Matthew L. Sherman, Gege Tan,

2024年8月16日 · The FDA has accepted and granted priority review to a new drug application (NDA) for vimseltinib (DCC-3014), a colony-stimulating factor 1 receptor (CSF1R)-directed therapy, for the treatment of...

DCC-3014 –Highly Selective CSF1R Kinase Inhibitor 3 •DCC-3014 is a highly selective, oral, investigational switch control kinase inhibitor that exhibits nanomolar potency for CSF1R with >100-fold selectivity vs closely related kinases (KIT, PDGFRα, PDGFRβ, and FLT3)1 •DCC-3014 inhibits CSF1R signaling in cellular assays, as well as blocks

2021年5月28日 · DCC-3014 is an inhibitor of the CSF1R kinase that decreases tumor infiltrating myeloid cells in preclinical models. We hypothesized that DCC-3014 combined with the anti-PDL1 inhibitor avelumab would be safe and tolerable, decrease immunosuppressive myeloid cells, and increase cytotoxic T cells.

• DCC-3014 is an orally administered, potent, and selective inhibitor of CSF1R that was engineered to bind into the CSF1R switch pocket and inhibit kinase activity5 – DCC-3014 potently inhibits CSF1R signaling in cellular assays, as well as functionally blocks macrophage-mediated tumor cell migration, osteoclast

2017年6月1日 · Deciphera is scheduled to reveal updated phase 1 data on its tumor resistance-targeting candidate DCC-2618 at the big oncology meeting in Chicago, and said it will use the new funds to push that...

Vimseltinib, also known as DCC-3014, is an investigational drug that works as a colony-stimulating factor 1 receptor (CSF1R) inhibitor. It is being studied for its potential to treat conditions like chronic graft-versus-host disease (cGVHD) and tenosynovial giant cell tumors (TGCT) by targeting specific cellular pathways involved in these diseases.